In the article by Akhtar et al, which appeared in the April 2013 issue of the journal (Arterioscler Thromb Vasc Biol. 2013;33:679–686. DOI: 10.1161/ATVBAHA.112.301162), the article requires the following changes:
1. On page 681, in the “Effects of CXCL12 Treatment on Lesion Composition” section, on line 6, only Figure 2A should have been referenced. In the same section, on line 9, Figure 2C should have been referenced.
2. On page 683, the 2nd paragraph of the first column, the sentence starting with “The lesion…” should have been: The lesion size and lesional macrophage content, as determined by elastic Van Gieson staining and Mac2 immunostaining, respective, were increased, whereas the lesional SMC content (SM22+ immunostaining) was decreased in mice treated with…”
3. On page 685, in the first column, 15 lines from the bottom, the sentence starting with “However, the lesion…” should have been: However, the lesion phenotype was substantially changed by CXCL12 treatment, resulting in increased infiltration of inflammatory cells and lesional accumulation…”
The online version of the article has been corrected and is available at http://atvb.ahajournals.org/content/33/4/679.full.
- © 2013 American Heart Association, Inc.